16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008.

OBJECTIVES We analyzed the infection burden associated with the implantation of cardiac implantable electrophysiological devices (CIEDs) in the United States for the years 1993 to 2008. BACKGROUND Recent data suggest that the rate of infection following CIED implantation may be increasing. METHODS The Nationwide Inpatient Sample (NIS) discharge records were queried between 1993 and 2008 using the 9th Revision of the International Classification of Diseases (ICD-9-CM). CIED infection was defined as either: 1) ICD-9 code for device-related infection (996.61) and any CIED procedure or removal code; or 2) CIED procedure code along with systemic infection. Patient health profile was evaluated by coding for renal failure, heart failure, respiratory failure, and diabetes mellitus. The infection burden and patient health profile were calculated for each year, and linear regression was used to test for changes over time. RESULTS During the study period (1993 to 2008), the incidence of CIED infection was 1.61%. The annual rate of infections remained constant until 2004, when a marked increase was observed, which coincided with an increase in the incidence of major comorbidities. This was associated with a marked increase in mortality and in-hospital financial charges. CONCLUSIONS The infection burden associated with CIED implantation is increasing over time and is associated with prolonged hospital stays and high financial costs.

[1]  R. Darouiche,et al.  Treatment of infections associated with surgical implants. , 2004, The New England journal of medicine.

[2]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[3]  S. Saba,et al.  Continued Rise in Rates of Cardiovascular Implantable Electronic Device Infections in the United States: Temporal Trends and Causative Insights , 2010, Pacing and clinical electrophysiology : PACE.

[4]  L. Baddour,et al.  Temporal trends in permanent pacemaker implantation: a population-based study. , 2008, American heart journal.

[5]  Daniel R. Frisch,et al.  Implantation Trends and Patient Profiles for Pacemakers and Implantable Cardioverter Defibrillators in the United States: 1993–2006 , 2010, Pacing and clinical electrophysiology : PACE.

[6]  Robert J. Myerburg,et al.  Implantable cardioverter-defibrillators after myocardial infarction. , 2008, The New England journal of medicine.

[7]  T. Ferguson,et al.  The additional hospital costs generated in the management of complications of pacemaker and defibrillator implantations. , 1996, The Journal of thoracic and cardiovascular surgery.

[8]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[9]  P. Heidenreich,et al.  Gender Differences in Procedure-Related Adverse Events in Patients Receiving Implantable Cardioverter-Defibrillator Therapy , 2009, Circulation.

[10]  D. Wennberg,et al.  The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. , 2005, Journal of the American College of Cardiology.

[11]  David L Hayes,et al.  Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. , 2007, Journal of the American College of Cardiology.

[12]  J. Healey,et al.  Device‐Related Infection Among Patients With Pacemakers and Implantable Defibrillators: Incidence, Risk Factors, and Consequences , 2010, Journal of cardiovascular electrophysiology.

[13]  David L Hayes,et al.  Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. , 2007, Archives of internal medicine.

[14]  Jeroen J. Bax,et al.  Recurrent Implantable Cardioverter‐Defibrillator Replacement Is Associated with an Increasing Risk of Pocket‐Related Complications , 2010, Pacing and clinical electrophysiology : PACE.

[15]  M. Gold Complication Rates Associated With Pacemaker or Implantable Cardioverter-Defibrillator Generator Replacements and Upgrade Procedures: Results From the REPLACE Registry , 2011 .

[16]  R. Passman,et al.  Increased complication rates of cardiac rhythm management devices in ESRD patients. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  H. Krumholz,et al.  Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. , 2009, JAMA.

[18]  M. Mcclellan,et al.  Medicare coverage of ICDs. , 2005, The New England journal of medicine.

[19]  Walter R Wilson,et al.  Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. , 2010, Circulation.

[20]  Wojciech Zareba,et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. , 2002, The New England journal of medicine.

[21]  H. Mond,et al.  The World Survey of Cardiac Pacingand Cardioverter‐Defibrillators: Calendar Year 2005 An International Cardiac Pacing andElectrophysiology Society (ICPES) project , 2008, Pacing and clinical electrophysiology : PACE.

[22]  Paul A. Heidenreich,et al.  Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. , 2004 .

[23]  Daniel B. Mark,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure , 2005 .